The impact of early discontinuation/dose modification of venetoclax on outcomes in patients with relapsed/refractory chronic lymphocytic leukemia: post-hoc analyses from the phase III MURANO study

Fixed-duration venetoclax plus rituximab (VenR) has a manageable safety profile and improves survival in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). We present data from the phase III MURANO study on the impact of venetoclax modification or premature discontinuation o...

Descripción completa

Detalles Bibliográficos
Autores principales: Mato, Anthony R., Sharman, Jeff P., Biondo, Juliana M.L., Wu, Mei, Mun, Yong, Kim, Su Y., Humphrey, Kathryn, Boyer, Michelle, Zhu, Qian, Seymour, John F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8719076/
https://www.ncbi.nlm.nih.gov/pubmed/33327712
http://dx.doi.org/10.3324/haematol.2020.266486

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8719076/
https://www.ncbi.nlm.nih.gov/pubmed/33327712
http://dx.doi.org/10.3324/haematol.2020.266486

Ejemplares similares